CMV Pneumonia in Pregnancy When Valganciclovir Has Not Resolved Symptoms

Clinical Scenario

This protocol addresses cytomegalovirus (CMV) pneumonia occurring during pregnancy. Indications for treating CMV infection in pregnancy are the same as for other patients with HIV. Valganciclovir is the preferred first-line agent for maternal CMV disease.

When First-Line Therapy Has Failed

This protocol applies when valganciclovir — the standard preferred regimen — has not achieved resolution of CMV pneumonia signs and symptoms: persistent fever, cough or dyspnoea, and diffuse pulmonary interstitial infiltrates, despite a course of at least 21 days.

Next-Line Approach (Partial Overview)

In this setting, alternative antiviral agents — notably foscarnet — may be considered, but only in close consultation with a maternal–fetal medicine specialist. The complete regimen, selection criteria, and monitoring requirements are detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

During pregnancy, indications for treatment of CMV infection are the same as for other people with HIV (AIII).

Valganciclovir is the preferred treatment for maternal CMV disease during pregnancy (BIII).

Foscarnet and cidofovir are not recommended in the absence of resistance or toxicity with ganciclovir/valganciclovir (AIII); use of foscarnet and cidofovir should only be done in consultation with a maternal–fetal medicine specialist, and additional fetal surveillance may be recommended in the setting of maternal renal insufficiency (BIII).

View source ↗